Literature DB >> 3696835

Cefixime: spectrum of antibacterial activity against 16,016 clinical isolates.

A L Barry1, R N Jones.   

Abstract

The spectrum of antibacterial activity of cefixime was defined by reviewing data from two multicenter studies and three independent studies that we performed within the past 3 years. Microdilution tests were performed with 16,016 bacterial isolates. An isolate was considered susceptible to cefixime if the minimal inhibitory concentration was less than or equal to 1.0 microgram/ml and resistant if the minimal inhibitory concentration was greater than or equal to 4.0 micrograms/ml. Cefixime was effective against the Enterobacteriaceae (87.7% susceptible to 1.0 microgram/ml) as well as against pathogenic Neisseria spp. (including penicillin-resistant gonococci), Haemophilus influenzae (including ampicillin-resistant strains), penicillin-susceptible Streptococcus pneumoniae and other Streptococcus species (minimal concentration inhibiting 90% of organisms less than or equal to 0.25 micrograms/ml). Species resistant to cefixime included penicillin-resistant pneumococci, Staphylococcus spp., Enterococcus spp., Listeria spp., Acinetobacter spp. and Pseudomonas spp.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3696835

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  13 in total

1.  In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.

Authors:  T U Westblom; S Gudipati; B R Midkiff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

2.  [Clinical experiences with cefixime in the treatment of bacterial infections of the lower respiratory tract].

Authors:  W Kersten; H Müsken
Journal:  Infection       Date:  1990       Impact factor: 3.553

3.  [Therapy of pediatric infections with cefixime].

Authors:  H Helwig
Journal:  Infection       Date:  1990       Impact factor: 3.553

4.  [Cefixime therapy in patients with proven gonorrhea].

Authors:  A Backhaus; J Tinzl
Journal:  Infection       Date:  1990       Impact factor: 3.553

5.  Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis.

Authors:  A Verghese; D Roberson; J H Kalbfleisch; F Sarubbi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Methods for predicting susceptibility of Streptococcus pneumoniae to cefixime.

Authors:  A L Barry; P C Fuchs
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

Review 7.  Antimicrobial agents for community-acquired respiratory tract infections.

Authors:  A L Barry
Journal:  Infection       Date:  1995       Impact factor: 3.553

8.  Antimicrobial activity and beta-lactamase stability of BMY-28232, parent compound of an oral cephalosporin.

Authors:  N X Chin; K W Yu; H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

Review 9.  Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.

Authors:  A Markham; R N Brogden
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

10.  Cefixime penetration in human renal parenchyma.

Authors:  A Leroy; B Oser; P Grise; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.